MARKET

CI

CI

Cigna Group
NYSE
352.69
-1.82
-0.51%
Opening 12:12 04/26 EDT
OPEN
353.69
PREV CLOSE
354.51
HIGH
354.42
LOW
351.46
VOLUME
313.25K
TURNOVER
0
52 WEEK HIGH
365.71
52 WEEK LOW
236.21
MARKET CAP
100.04B
P/E (TTM)
20.28
1D
5D
1M
3M
1Y
5Y
Cigna's Evernorth to Offer Humira Biosimilar Without Out-of-Pocket Fee
Cigna-owned Evernorth Health Services says it will provide a Humira biosimilar with no out-of-pocket fees starting in June. The company says the biosimilar price would be about 85% lower than the Humira list price. Humira is used as a treatment for rheumatoid arthritis, Crohn's disease.
Dow Jones · 19h ago
CIGNA GROUP SAYS EVERNORTH ANNOUNCES HUMIRA BIOSIMILAR AVAILABLE AT $0 OUT OF POCKET FOR ACCREDO PATIENTS IN JUNE
Reuters · 19h ago
CIGNA SAYS BIOSIMILAR TO ABBVIE'S HUMIRA WILL BE AVAILABLE THROUGH AGREEMENTS WITH MULTIPLE MANUFACTURERS
Reuters · 19h ago
Evernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June
Evernorth Health Services will have a Humira biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy Accredo beginning this June. The biosimilar price will be about 85% lower than the list price for Humira®. The program is estimated to save individual patients around $3,500 on average per year. High- and low-concentration interchangeable biosimilar will be available.
PR Newswire · 19h ago
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Cigna to offer close copies of AbbVie's arthritis drug Humira with $0 copay at specialty pharmacy beginning in June. The company will stock biosimilar versions of the drug at its Accredo pharmacy in the U.S. Cigna says the move should save eligible patients $3,500 per year. Abbvie has held onto 98% of the Humira market.
Reuters · 19h ago
EVERNORTH HEALTH SERVICES - HIGH- AND LOW-CONCENTRATION INTERCHANGEABLE BIOSIMILAR WILL BE PRODUCED FOR QUALLENT PHARMACEUTICALS
Reuters · 19h ago
Daily Dividend Report: PFE, SCHW, CI, MPC, AVY
NASDAQ · 22h ago
Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies
Walgreens Boots Alliance expands specialty pharmacy with unit dedicated to cell and gene therapies. Walgreens expects to be largest provider of specialty pharmacy services with $24B in annual revenue. The company's focus on gene and cell therapies comes months after first gene-editing therapy was approved.
Seeking Alpha · 1d ago
More
About CI
The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. The Company’s portfolio of offerings solves diverse challenges across the healthcare system. Evernorth Health Services includes a range of independent and coordinated health solutions and capabilities designed to enable the healthcare system to help people live richer, healthier lives. Health plans, employers, governmental organizations and health care providers partner with Evernorth Health Services to solve their challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. Cigna Healthcare includes the United States healthcare and international health businesses, which provide comprehensive medical and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI) and the Company's run-off operations.

Webull offers Cigna Group stock information, including NYSE: CI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CI stock methods without spending real money on the virtual paper trading platform.